Ghent University Academic Bibliography

Advanced

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Gaafar, Rabab M, Surmont, Veerle UGent, Scagliotti, Giorgio V, Van Klaveren, Rob J, Papamichael, Demetris, Welch, John J, Hasan, Baktiar, Torri, Valter and Van Meerbeeck, Jan UGent (2011) EUROPEAN JOURNAL OF CANCER. 47(15). p.2331-2340
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
CELL LUNG-CANCER, SUPPORTIVE CARE, TRIAL, CARBOPLATIN, DOCETAXEL, ERLOTINIB, GEMCITABINE, COMBINATION, PACLITAXEL, PLUS, EORTC, EGFR, Gefitinib, Chemotherapy, Non-small cell lung cancer
journal title
EUROPEAN JOURNAL OF CANCER
Eur. J. Cancer
volume
47
issue
15
pages
2331 - 2340
Web of Science type
Article
Web of Science id
000296393700011
JCR category
ONCOLOGY
JCR impact factor
5.536 (2011)
JCR rank
25/190 (2011)
JCR quartile
1 (2011)
ISSN
0959-8049
DOI
10.1016/j.ejca.2011.06.045
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2044481
handle
http://hdl.handle.net/1854/LU-2044481
date created
2012-02-24 15:29:53
date last changed
2016-12-19 15:45:05
@article{2044481,
  author       = {Gaafar, Rabab M and Surmont, Veerle and Scagliotti, Giorgio V and Van Klaveren, Rob J and Papamichael, Demetris and Welch, John J and Hasan, Baktiar and Torri, Valter and Van Meerbeeck, Jan},
  issn         = {0959-8049},
  journal      = {EUROPEAN JOURNAL OF CANCER},
  keyword      = {CELL LUNG-CANCER,SUPPORTIVE CARE,TRIAL,CARBOPLATIN,DOCETAXEL,ERLOTINIB,GEMCITABINE,COMBINATION,PACLITAXEL,PLUS,EORTC,EGFR,Gefitinib,Chemotherapy,Non-small cell lung cancer},
  language     = {eng},
  number       = {15},
  pages        = {2331--2340},
  title        = {A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)},
  url          = {http://dx.doi.org/10.1016/j.ejca.2011.06.045},
  volume       = {47},
  year         = {2011},
}

Chicago
Gaafar, Rabab M, Veerle Surmont, Giorgio V Scagliotti, Rob J Van Klaveren, Demetris Papamichael, John J Welch, Baktiar Hasan, Valter Torri, and Jan Van Meerbeeck. 2011. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” European Journal of Cancer 47 (15): 2331–2340.
APA
Gaafar, R. M., Surmont, V., Scagliotti, G. V., Van Klaveren, R. J., Papamichael, D., Welch, J. J., Hasan, B., et al. (2011). A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER, 47(15), 2331–2340.
Vancouver
1.
Gaafar RM, Surmont V, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER. 2011;47(15):2331–40.
MLA
Gaafar, Rabab M, Veerle Surmont, Giorgio V Scagliotti, et al. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” EUROPEAN JOURNAL OF CANCER 47.15 (2011): 2331–2340. Print.